We have identified you may not be viewing TRAVAX optimally because the browser you are using is unsupported - click here.
The World Health Organization reports continuing transmission of mpox in Africa. Countries reporting laboratory-confirmed cases from 1 January 2024 to the latest update of 22 September 2024 are:
Democratic Republic of the Congo: 5 261 cases (25 deaths)
Burundi: 696 cases
Nigeria: 55 cases
Central African Republic: 54 cases (1 death)
Côte d’Ivoire: 52 cases (1 death)
South Africa: 25 (3 deaths)
Uganda: 22 cases
Congo: 21 cases
Liberia: 12 cases
Cameroon: 6 cases (2 deaths)
Rwanda: 6 cases
Kenya: 5 cases
Gabon: 2 cases
Morocco: 2 cases
Guinea: 1 case
Mpox is a zoonotic infection that is rarely seen in travellers arriving from African countries.
Transmission between people occurs through close skin to skin contact (including during sexual contact), or through droplet spread during close contact with a person infected with mpox.
Symptoms in people commence with fever, a flu-like illness and swollen glands followed by the development of a blistering skin rash, resembling chickenpox.
Travellers should:
Travellers to any destination who may be sexually active during travel (including GBMSM) should:
Travellers should be advised to seek medical help during, or for 21 days after travel if they develop symptoms of mpox and have:
While a vaccine specifically against mpox is not available, the smallpox vaccine provides some protection.
The United Kingdom Health Security Agency (UKHSA) classifies Clade I mpox (Central Africa) as a high consequence infectious disease (HCID). Operational case definitions are published here.
For further information see Mpox, Sexual Health Risks and LGBT travellers
Advice to travellers will be updated as appropriate.